Literature DB >> 26679684

Late Complications After Endoscopic Sphincterotomy.

Melissa Oliveira-Cunha1, Ashley R Dennison, Giuseppe Garcea.   

Abstract

The introduction of endoscopic retrograde cholangiopancreatography with endoscopic sphincterotomy (ES) has changed the treatment of choledocholithiasis. An increasing number of young patients are requiring ES, and this raises concern regarding any potential long-term complications arising from irreversibly altering the anatomy of the sphincter of Oddi. In particular, concern has been raised regarding the risk of late cholangiocarcioma. A review was performed evaluating the relationship between ES for benign disease and the subsequent development of late complications, including biliary tract malignancy, the formation of primary duct stones, and recurring cholangitis. A systematic review of articles published between 1970 and 2013 was undertaken. Current evidence shows that ES is a safe and effective treatment for common bile duct stones. The long-term risk of subsequent cholangiocarcinoma has not been convincingly proven although in many of these studies the follow-up period was inadequate. There does appear to be an associated increased incidence of cholangiocarcinomas following sphincterotomy although this is not proven to be causative. If there is an increased risk of cholangiocarcinoma following ES, it is likely to be small in western populations. However, until longer follow-up studies are published, it may be prudent to avoid ES in the very young.

Entities:  

Mesh:

Year:  2016        PMID: 26679684     DOI: 10.1097/SLE.0000000000000226

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  7 in total

1.  Predictors for stone recurrence after a successful common bile duct surgical exploration for choledocholithiasis.

Authors:  Paula Gonzálvez-Guardiola; Carmen Payá-Llorente; Carlos Domingo-Del Pozo; Aleix Martínez-Pérez
Journal:  Langenbecks Arch Surg       Date:  2022-06-07       Impact factor: 2.895

2.  Laparoscopic common bile duct exploration in patients with previous abdominal biliary tract operations.

Authors:  Min Li; Ying Tao; Sheng Shen; Lujun Song; Tao Suo; Han Liu; Yueqi Wang; Dexiang Zhang; Xiaoling Ni; Houbao Liu
Journal:  Surg Endosc       Date:  2020-02-18       Impact factor: 4.584

3.  Clinical efficacy, timing, and outcomes of ERCP for management of bile duct leaks: a nationwide cohort study.

Authors:  Aakash Desai; Patrick Twohig; Sophie Trujillo; Shaman Dalal; Gursimran S Kochhar; Dalbir S Sandhu
Journal:  Endosc Int Open       Date:  2021-02-03

4.  Cholecystectomy reduces subsequent cholangiocarcinoma risk in choledocholithiasis patients undergoing endoscopic intervention.

Authors:  Chi-Chih Wang; Ming-Hseng Tseng; Sheng-Wen Wu; Tzu-Wei Yang; Hsuan-Yi Chen; Wen-Wei Sung; Chang-Cheng Su; Yao-Tung Wang; Chun-Che Lin; Ming-Chang Tsai
Journal:  World J Gastrointest Oncol       Date:  2020-12-15

5.  A nomogram for predicting stones recurrence in patients with bile duct stones undergoing laparoscopic common bile duct exploration.

Authors:  Wangcheng Xie; Tingsong Yang; Xue Zhou; Zhilong Ma; Weidi Yu; Guodong Song; Zhengyu Hu; Jian Gong; Yuxiang Wang; Zhenshun Song
Journal:  Ann Gastroenterol Surg       Date:  2022-02-22

Review 6.  Safety and efficacy of laparoscopic common bile duct exploration for the patients with difficult biliary stones: 8 years of experiences at a single institution and literature review.

Authors:  Zhilong Ma; Jia Zhou; Le Yao; Yuxiang Dai; Wangcheng Xie; Guodong Song; Hongbo Meng; Bin Xu; Ti Zhang; Bo Zhou; Tingsong Yang; Zhenshun Song
Journal:  Surg Endosc       Date:  2021-02-22       Impact factor: 4.584

7.  Increased Risk of Pyogenic Liver Abscess after Endoscopic Sphincterotomy for Treatment of Choledocholithiasis.

Authors:  Cheng-Kun Wu; Chien-Ning Hsu; Wei-Ru Cho; Shih-Cheng Yang; An-Che Liu; Wei-Chen Tai; Chen-Hsiang Lee; Yao-Hsu Yang; Seng-Kee Chuah; Chih-Ming Liang
Journal:  Infect Drug Resist       Date:  2021-06-08       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.